Does tamoxifen prophylaxis for breast cancer provide long-term prevention?
Bernardo Bonanni, Matteo Lazzeroni and Umberto Veronesi*
Correspondence *Istituto Europeo di Oncologia, Via G Ripamonti 435, 20141 Milan, Italy
Email umberto.veronesi@ieo.it
This article has no abstract so we have provided the first paragraph of the full text.
Cuzick et al. have reported long-term results from the IBIS-I trial, a randomized placebo-controlled study of 5 years' tamoxifen for the primary prevention of breast cancer in 7,145 women at high risk of disease. The primary end point was breast cancer incidence. The initial results of the trial had already shown a 31% risk reduction for ER-positive breast cancer incidence in the tamoxifen arm, and a reasonable safety during treatment.1
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.